TIRZEPATIDE FOR CARDIOVASCULAR RISK REDUCTION: A LITERATURE REVIEW
Abstract
Background: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, shows promise beyond glycemic control for managing cardiovascular risk factors. Recent studies suggest that tirzepatide may also offer cardiovascular benefits by improving weight, glycemic control, blood pressure, systemic inflammation, and cardiometabolic risk factors.
Aim: Our review summarizes the current evidence on tirzepatide’s cardiovascular effects, mechanisms of action, clinical outcomes, and safety profile in populations at increased cardiovascular risk.
Methodology: We conducted a narrative literature review of tirzepatide and cardiovascular outcomes using PubMed and Google Scholar.
Conclusion: Tirzepatide appears to be a promising therapeutic option for reducing cardiovascular risk, particularly in patients with type 2 diabetes, obesity, and heart failure. Current data support its positive effects on multiple cardiovascular risk factors. However, further confirmation from large clinical trials is needed to fully establish its long-term benefits and safety.
References
Augusto, S. N., Kaelber, D., & Tang, W. H. W. (2025). Real-world efficacy of tirzepatide in patients with heart failure without diabetes. Current Problems in Cardiology, 50(4), 102998. https://doi.org/10.1016/j.cpcardiol.2025.102998
Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017). Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials. Diabetes, Obesity and Metabolism, 19(3), 336–347. https://doi.org/10.1111/dom.12824
Borlaug, B. A., Zile, M. R., Kramer, C. M., Baum, S. J., Hurt, K., Litwin, S. E., Murakami, M., Ou, Y., Upadhyay, N., & Packer, M. (2025). Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: A secondary analysis of the SUMMIT trial. Nature Medicine, 31(2), 544–551. https://doi.org/10.1038/s41591-024-03374-z
Created in BioRender. Layla, L. (2025) https://BioRender.com/v0bumom. (n.d.). [Graphic].
Dani, S. S., Makwana, B., Khadke, S., Kumar, A., Jhund, P., Nasir, K., Sattar, N., Al-Kindi, S., Fonarow, G., Butler, J., Bhatt, D. L., Kosiborod, M. N., Nohria, A., & Ganatra, S. (2025). An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists. JACC: Advances, 4(5), 101740. https://doi.org/10.1016/j.jacadv.2025.101740
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014). Adverse Effects of GLP-1 Receptor Agonists. The Review of Diabetic Studies, 11(3–4), 202–230. https://doi.org/10.1900/RDS.2014.11.202
Frias, J. P., Nauck, M. A., Van, J., Benson, C., Bray, R., Cui, X., Milicevic, Z., Urva, S., Haupt, A., & Robins, D. A. (2020). Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens. Diabetes, Obesity and Metabolism, 22(6), 938–946. https://doi.org/10.1111/dom.13979
Hegedűs, Z. I., Jakab, M. E., Gergely, T. G., Sayour, N. V., Kovács, A., Antal, S., Kovács, T., Ferdinandy, P., Varga, Z. V., & Tóth, V. E. (2025). Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: Comparison to liraglutide. Cardiovascular Diabetology, 24(1), 253. https://doi.org/10.1186/s12933-025-02806-5
Jensen, T. L., Brønden, A., Karstoft, K., Sonne, D. P., & Christensen, M. B. (2024). The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects. Patient Preference and Adherence, 18, 373–382. https://doi.org/10.2147/PPA.S419304
Krumholz, H. M., De Lemos, J. A., Sattar, N., Linetzky, B., Sharma, P., Mast, C. J., Ahmad, N. N., Bunck, M. C., & Stefanski, A. (2024). Tirzepatide and blood pressure reduction: Stratified analyses of the SURMOUNT-1 randomised controlled trial. Heart, 110(19), 1165–1171. https://doi.org/10.1136/heartjnl-2024-324170
Lin, Y.-M., Liao, K.-M., Yu, T., Wu, J.-Y., & Lai, C.-C. (2025). Effectiveness of tirzepatide in patients with HFpEF using a target trial emulation retrospective cohort study. Nature Communications, 16(1), 4471. https://doi.org/10.1038/s41467-025-59616-2
Luna-Marco, C., Iannantuoni, F., Hermo-Argibay, A., Devos, D., Salazar, J. D., Víctor, V. M., & Rovira-Llopis, S. (2024). Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress. Free Radical Biology and Medicine, 213, 19–35. https://doi.org/10.1016/j.freeradbiomed.2024.01.015
Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., Hurt, K. C., Murakami, M., & Borlaug, B. A. (2025). Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine, 392(5), 427–437. https://doi.org/10.1056/NEJMoa2410027
Sattar, N., McGuire, D. K., Pavo, I., Weerakkody, G. J., Nishiyama, H., Wiese, R. J., & Zoungas, S. (2022). Tirzepatide cardiovascular event risk assessment: A pre-specified meta-analysis. Nature Medicine, 28(3), 591–598. https://doi.org/10.1038/s41591-022-01707-4
Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024). New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists. Biomedicines, 12(6), 1320. https://doi.org/10.3390/biomedicines12061320
Taktaz, F., Fontanella, R. A., Scisciola, L., Pesapane, A., Basilicata, M. G., Ghosh, P., Franzese, M., Tortorella, G., Puocci, A., Vietri, M. T., Capuano, A., Paolisso, G., & Barbieri, M. (2024). Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: Evidence for the role of tirzepatide. Cardiovascular Diabetology, 23(1), 242. https://doi.org/10.1186/s12933-024-02319-7
Yang, J., Gu, Y., Chen, H., Wang, H., Hong, L., Li, B., & Yang, L. (2024). Tirzepatide’s innovative applications in the management of type 2 diabetes and its future prospects in cardiovascular health. Frontiers in Pharmacology, 15, 1453825. https://doi.org/10.3389/fphar.2024.1453825
Views:
67
Downloads:
33
Copyright (c) 2025 Elhatra Settaf-Cherif, Layla Settaf-Cherif, Katarzyna Malinowska, Joanna Barwacz, Dagmara Gładysz, Magdalena Adamik
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
